Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check7 days agoChange DetectedAdded Hepatocellular carcinoma to the list of conditions and updated the study version from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page revision tag was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedAdded 'Gastric cancer' under Conditions and introduced a new Resources link to the Genetic and Rare Diseases Information Center. Removed the older Revision: v3.4.1 entry.SummaryDifference0.2%

- Check50 days agoChange DetectedThe revision label updated from v3.4.0 to v3.4.1. This appears to be a version update with no impact on the study details or page content.SummaryDifference0.0%

- Check64 days agoChange DetectedAnticoagulation guidance updated to allow therapeutic LMWH under specified conditions and eligibility/safety criteria revised across GI cancer cohorts; baseline requirements and related notes were updated.SummaryDifference1%

- Check72 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4. No visible changes to study details, eligibility criteria, or other core content.SummaryDifference0.0%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.